Gilead Sciences Again Named to Dow Jones Sustainability World Index

DJSI World Highlights the Most Sustainable Companies Around the World Based on Corporate Sustainability Assessment –

– Ranking Reflects Gilead's Ongoing Commitment to Corporate Responsibility –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World). This ranking is based on an in-depth analysis of Gilead's sustainability performance and highlights the company's longstanding sustainable business practices and transparency on environmental, social and governance (ESG) issues.

"We are very pleased to receive this recognition once again, as a reflection of our commitment to patients, local communities, society and the planet," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. "Corporate responsibility is inherent in everything Gilead does, as we work toward our vision of making the world a healthier place for all people."

Gilead's ESG strategy aims to position the company as an employer of choice that delivers shareholder value in a responsible manner. Examples of Gilead's commitment to ESG include:

  • Expanding health equity around the world through programs that promote health system sustainability, strengthen infrastructure and provide education and financial support
  • Increasing access to medicines in low- and lower-middle income countries, including royalty-free voluntary licensing for Gilead's antiviral treatment for COVID-19
  • Creating an inclusive workplace that is representative of the diverse communities the company serves
  • Continuing to evolve the company's environmental sustainability program and reducing greenhouse gas emissions, minimizing waste generation and using resources efficiently

The DJSI World applies a transparent, rules-based constituent selection process based on the companies' S&P Global ESG Score resulting from the annual S&P Global Corporate Sustainability Assessment (CSA). The CSA consists of a rigorous questionnaire assessing both public and non-public data submitted by participating companies. This year, more than 10,000 publicly traded companies were invited to participate in the S&P Global CSA.

Details on Gilead's ESG commitments, goals and progress can be found in the company's Year in Review , which is based on internationally recognized guidelines from the Global Reporting Initiative, the Sustainability Accounting Standards Board, the Taskforce on Climate Related Financial Disclosures and the United Nations Sustainable Development Goals. Learn more about Gilead's commitment to ESG and corporate responsibility at https://www.gilead.com/purpose/sustainability .

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, inflammation and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-   GILEAD-5 or 1-650-574-3000.

Jacquie Ross, Investors
Investor_relations@gilead.com

Hayley Home, Media
Public_affairs@gilead.com

News Provided by Business Wire via QuoteMedia

GILD
The Conversation (0)
CHMP Adopts Positive Opinion Recommending Hepcludex®  for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

CHMP Adopts Positive Opinion Recommending Hepcludex® for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

--   If Granted by the European Commission, Hepcludex will Become the Only Approved Treatment for HDV in the EU --

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Hepcludex ® (bulevirtide) for the treatment of adults with chronic HDV and compensated liver disease, and recommended granting full Marketing Authorisation (MA) that is no longer subject to specific obligations. Bulevirtide was initially granted conditional marketing authorisation in July 2020 to provide people living with HDV urgent access to treatment. The CHMP recommendation for full Marketing Authorisation of bulevirtide follows the submission of the Phase 3 MYR301 Week 48 study data, which reinforces the efficacy and safety profile of bulevirtide for the treatment of HDV.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination. Gilead is proud that its medicines have treated over four million individuals living with HCV globally. Today, some 2.4 million people are living with HCV in the U.S., even though ~95% of those treated with direct-acting antivirals (DAAs) are cured. Prices of HCV medicines have dropped significantly, and many acknowledge that price is not a barrier for most payers and patients. Curative HCV drug therapies are just one part of an elimination strategy that needs to dedicate considerable resources and attention to screening and linkage to care so that all patients in need of HCV treatment can access it in a timely manner and achieve a cure

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Gilead Sciences Announces First Quarter 2023 Financial Results

Gilead Sciences Announces First Quarter 2023 Financial Results

Product Sales Excluding Veklury Increased 15% Year-Over-Year to $5.7 billion

Biktarvy Sales Increased 24% Year-Over-Year to $2.7 billion

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences recently released its inaugural Environmental, Social and Governance (ESG) Impact Report. This is an evolution of our traditional Year in Review, and uses the ESG framework to highlight the successes and achievements of the prior year

Though the report itself is new, our commitment to practicing ESG is not: We've been guided by Environmental, Social and Governance principles for more than 35 years.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
abigail echo-hawk

CORRECTION: Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve the Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

Enables Contakt World mission to improve health equity and reduce disparities in the fight against Covid-19 and all diseases via award-winning SaaS platform

This document corrects and updates the final paragraph in the body of this news release. No other changes were required in this release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×